Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Siltuximab plus Bortezomib in Relapsed/Refractory Multiple Myeloma
NCT00401843Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2006
- Primary completion
- Aug 2011
- Modality
- Monoclonal Antibodies
- Countries
- 18
01
Overview
A Phase 2 trial of siltuximab in multiple myeloma (MM), sponsored by Janssen Pharmaceutical. Started Nov 2006; status: completed.
02
Drugs
siltuximab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00401843.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00401843.